An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients.
Lung cancer is the leading cause of cancer death in Australia and worldwide, with a five-year survival rate of only 17 per cent.
The ASPiRATION program is a pioneering partnership between Government, industry and academia. The program is led by the Thoracic Oncology Group of Australasia (TOGA) [formerly the Australasian Lung Cancer Trials Group (ALTG)] in collaboration with Omico and the NHMRC Clinical Trials Centre (CTC). The program is supported by funding from the federal government’s Medical Research Future Fund (MRFF) and Roche.
The ASPiRATION study is the first of its kind in Australia to generate high-quality, real-world data about the impact and value of comprehensive genomic profiling (CGP) in delivering precision medicine and personalised healthcare. Identifying actionable molecular targets through CGP provides patients with opportunities to receive novel targeted treatments via therapeutic substudies.
Molecular screening for ASPiRATION commenced in late 2020, with expansion to 15 participating hospitals throughout Australia planned by mid 2021. The first therapeutic substudy has commenced, four more substudies are nearing activation, and development is ongoing to bring more therapeutic substudies online this year.